Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (44)

2026

  1. Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies

    European Heart Journal Open, Vol. 6, Núm. 4

  2. Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 36, Núm. 4

  3. Corrigendum to ‘FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil’s proatherogenic phenotype which is modulated by semaglutide’(Journal of Molecular and Cellular Cardiology, (2026), 210, C, (12-27), (S0022282825001932), 10.1016/j.yjmcc.2025.10.009)

    Journal of Molecular and Cellular Cardiology

  4. External validation of atrial fibrillation risk scores in heart failure under continuous device surveillance

    Heart Rhythm, Vol. 23, Núm. 4, pp. e547-e556

  5. FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide

    Journal of Molecular and Cellular Cardiology, Vol. 210, pp. 12-27

  6. GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 148

  7. Left ventricular ejection fraction determines the pattern of left atrial remodeling in patients with heart failure without atrial fibrillation

    Clinical Research in Cardiology

2025

  1. Concomitant Diabetes and Atrial Fibrillation: Epicardial Fat and Macrophage-Related Mechanisms

    Diabetes/Metabolism Research and Reviews, Vol. 41, Núm. 5

  2. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation, Vol. 55, Núm. 4

  3. Plasma small extracellular vesicles: Markers and mediators of atrial scar, in patients with atrial fibrillation

    Heart Rhythm, Vol. 22, Núm. 12, pp. 3257-3267

  4. Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes

    JACC: Basic to Translational Science, Vol. 10, Núm. 9

  5. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry

    Revista Espanola de Cardiologia, Vol. 78, Núm. 3, pp. 218-228

2024

  1. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers

    Journal of Translational Medicine, Vol. 22, Núm. 1

  2. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry

    American Journal of Medicine, Vol. 137, Núm. 8, pp. 761-769.e1

  3. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  4. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 9, pp. e012683

  5. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

    Cardiovascular Diabetology, Vol. 23, Núm. 1

2023

  1. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  2. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1